Curevac N.V. (CVAC) has disclosed a new risk, in the Demand category.
Curevac N.V. faces considerable business risk as their market estimates for product candidates may not align with reality. Derived from various sources, their patient population calculations could be flawed, especially if new research alters disease incidence or prevalence understanding. Additionally, securing sufficient clinical trial participants poses a challenge, as individuals may resist their treatment methods. Even with market penetration, the small target demographics could render Curevac’s products unprofitable, irrespective of regulatory approval.
Overall, Wall Street has a Moderate Buy consensus rating on CVAC stock based on 1 Buy and 1 Hold.
To learn more about Curevac N.V.’s risk factors, click here.
